title: TMPRSS2 Met160Val polymorphism: significant association with sporadic prostate cancer, but not with latent prostate cancer in Japanese men.
abstract: OBJECTIVE
  To investigate the association between the TMPRSS2 Met160Val polymorphism and the risk of prostate cancer in Japanese men.
  
  
  METHODS
  Genomic DNA samples from 518 Japanese sporadic prostate cancer patients, 433 controls and 154 Japanese men who were diagnosed as having latent prostate cancer based on autopsy results were genotyped for the TMPRSS2 Met160Val polymorphism using a TaqMan assay. Logistic regression analyses were carried out to estimate the odds ratios and 95% confidence intervals. The relationship between the presence of the polymorphism, and clinicopathology and survival was also examined.
  
  
  RESULTS
  The T allele frequency of the control group was 0.372, of the sporadic prostate cancer group was 0.435 and of the latent prostate cancer group was 0.370. The CT and TT genotypes were significantly associated with risk for sporadic prostate cancer; age-adjusted odds ratios (95% confidence intervals) were 1.418 (1.027-1.960) for CT, 1.907 (1.224-2.990) for TT and 1.524 (1.123-2.072) for CT/TT genotypes. There was no significant association observed between the TMPRSS2 Met160Val polymorphism and the risk for latent prostate cancer. The TMPRSS2 Met160Val polymorphism was not significantly associated with any clinicopathological features or prognosis.
  
  
  CONCLUSIONS
  The TMPRSS2 Met160Val polymorphism is a genetic risk factor for sporadic prostate cancer in a Japanese population.
authors.affiliation: Department of Urology, The University of Tokyo, Tokyo, Japan.
authors.forename: Shigekatsu
authors.initials: S
authors.lastname: Maekawa
authors.forename: Motofumi
authors.initials: M
authors.lastname: Suzuki
authors.forename: Tomio
authors.initials: T
authors.lastname: Arai
authors.forename: Makoto
authors.initials: M
authors.lastname: Suzuki
authors.forename: Moriaki
authors.initials: M
authors.lastname: Kato
authors.forename: Teppei
authors.initials: T
authors.lastname: Morikawa
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kasuya
authors.forename: Haruki
authors.initials: H
authors.lastname: Kume
authors.forename: Tadaichi
authors.initials: T
authors.lastname: Kitamura
authors.forename: Yukio
authors.initials: Y
authors.lastname: Homma
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D004273:DNA, Neoplasm / Q000235:genetics*; D005838:Genotype; D006801:Humans; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction; D012189:Retrospective Studies; D012697:Serine Endopeptidases / Q000235:genetics* / Q000378:metabolism; D015996:Survival Rate / Q000639:trends
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D012697:Serine Endopeptidases; C421305:TMPRSS2 protein, human
keywords: TMPRSS2; latent prostate cancer; single nucleotide polymorphism; sporadic prostate cancer